We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Ionis Pharmaceuticals has entered a collaboration and licence agreement with Suzhou Ribo Life Science (Ribo) to develop and commercialise ribonucleic acid (RNA)-targeted therapeutics in China.